Consider establishing a long position in Ultragenyx Pharmaceutical Inc. (RARE), as the stock is deeply undervalued with high expectations for upcoming FDA gene therapy approvals.

Immediately avoid or divest from Quantum Computing Inc. (QCLS) due to toxic financing structures and anti-dilutive warrants that heavily disadvantage common shareholders.

Prepare for a steep decline in Sellas Life Sciences Group (SLS) over the next month ahead of anticipated poor clinical trial outcomes.

Look to trim positions or take profits on Advanced Micro Devices, Inc. (AMD) as it trades near the $150–$155 range, where cost increases from Taiwan Semiconductor Manufacturing Company (TSM) could pressure profit margins.

Treat micro-cap meme coins on platforms like Pump.fun strictly as fast, intraday trading opportunities rather than long-term investments due to extreme liquidity drain risks.

Ultragenyx Pharmaceutical Inc. (RARE)

• Described as "crazy cheap" and confirmed as a current long position.
• Discussed the company's gene therapy pipeline, specifically the candidate for Sanfilippo syndrome.
• Noted that CEO Emil Kakkis has a strong track record with FDA drug approvals.
• Mentioned the drug previously faced an FDA rejection, but attributed the primary issue to Chemistry, Manufacturing, and Controls (CMC) / manufacturing concerns rather than efficacy, expressing optimism that it should ultimately receive approval.

Takeaways

• Strongly bullish on the stock due to what is viewed as an excessively low valuation and positive expectations for upcoming regulatory drug approvals.

Quantum Computing Inc. (QCLS)

• The speaker announced quitting and resigning from any involvement with the company, along with his wife leaving the board of directors.
• Highlighted severe corporate structure risks, specifically "re-ratcheting" anti-dilutive warrants and structured financing held by PIPE (Private Investment in Public Equity) investors.
• Explained that warrant terms increase share counts and lower strike prices whenever new financing occurs, heavily diluting common shareholders to the point where common equity is described as effectively worthless ("toilet paper").
• Noted that warrant holders benefit when the stock price falls, creating a misaligned incentive where management and structured investors do not protect common stockholders.

Takeaways

• Strongly bearish and advised total avoidance due to toxic warrant structures, extreme dilution risk, and lack of alignment between leadership/warrant holders and common shareholders.

Revolution Medicines, Inc. (RVMD)

• Discussed looking into the stock and evaluating clinical data for darovasertib / RMC drugs (referred to in context of PDAC / pancreatic ductal adenocarcinoma).
• Mentioned using AI tools to model market sizing, penetration rates, and target patient populations in the U.S.
• Expressed potential interest in establishing a long position in the name.

Takeaways

• Constructive outlook based on upcoming oncology clinical data in pancreatic cancer, but further valuation and patient-market modeling is being evaluated.

Advanced Micro Devices, Inc. (AMD)

• Mentioned a recent rapid 10% run-up in the stock, nearing $150-$155.
• Noted that Taiwan Semiconductor Manufacturing Company (TSM) is raising prices, and those costs are being passed through to AMD.
• Expressed personal skepticism toward the rally ("sounds like a sale to me"), but self-reflected that he has historically mistimed AMD trades.

Takeaways

• Leaning bearish/cautious at current levels after a fast short-term surge, citing potential margin pressure from TSM pricing and historically tricky trade timing.

Biogen Inc. (BIIB)

• Reviewed the company’s recent press releases, market valuation, and pipeline partnerships (including commercial aspects related to Alzheimer's drug Leqembi).
• Initial review suggested the company is roughly fairly valued to potentially undervalued relative to its broader pipeline and market sales data.

Takeaways

• Neutral to mildly bullish; currently assessing pipeline performance and partner sales before making a high-conviction trade.

Sellas Life Sciences Group (SLS)

• Highly pessimistic about the company's clinical prospects.
• Stated an expectation that the stock is set to crash significantly once final clinical trial endpoints/patient outcomes conclude over the coming month.

Takeaways

• Bearish; anticipated downside driven by poor expected clinical outcomes.

Nokia Corporation (NOK)

• Discussed Nokia’s role in data business and AI infrastructure partnerships.
• Clarified that while Nokia is an optical and telecom data infrastructure play rather than a pure semiconductor company, it remains relevant in the AI data center supply chain.

Takeaways

• Neutral; acknowledged as a peripheral optical/networking player in the AI data center build-out, though not viewed as a core high-growth semiconductor asset.

Meme Coins / Micro-Cap Crypto (e.g., Pump.fun tokens)

• Engaged in short-term scalping of newly launched meme tokens on platforms like Pump.fun (e.g., "Feetcoin", "Testcoin").
• Emphasized that trading these assets is purely transactional short-term speculation aimed at quick profits rather than long-term investing.
• Warned that holding meme coins long-term is high risk due to rapid liquidity drains and lack of intrinsic value.

Takeaways

• High risk / purely speculative; suitable only for fast intraday scalping with strict risk controls, not long-term holding.